Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery
A phase 3 clinical trial, Alliance A071801, found that fractionated stereotactic radiosurgery (SRS) improved local control and overall survival for patients with brain metastases compared to single-fraction SRS. The findings suggest that fractionation offers a more tolerable and effective treatment approach for larger surgical cavities.
Why it matters
This study provides evidence-based guidance for oncologists to improve patient outcomes and reduce toxicity in the treatment of brain metastases.
CancerNetwork® spoke with Ayal Aizer, MD, MHS, director of Central Nervous System Radiation Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute and associate professor of radiation oncology at Harvard Medical School, about findings from the phase 3 Alliance A071801 trial (NCT04114981), which he presented as a late-breaking abstract during the plenary session at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in